Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04513808 | Total Intravenous Anesthesia and Recurrence Free Survival | recruiting | Phase 3 | 1,614 | The Cleveland ClinicOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07228832 | Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer(HARMONi-GI3) | recruiting | Phase 3 | 600 | Summit TherapeuticsINDUSTRY | 14 | Sep 8, 2026 | clinicaltrials |
| NCT07805954 | Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma(RASolute 309) | recruiting | Phase 3 | 400 | Revolution Medicines, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05677490 | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | recruiting | Phase 3 | 382 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT06252649 | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation(CodeBreaK 301) | recruiting | Phase 3 | 450 | AmgenINDUSTRY | 35 | Sep 3, 2026 | clinicaltrials |
| NCT06921785 | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma(ARTEMIDE-HCC01) | recruiting | Phase 3 | 1,220 | AstraZenecaINDUSTRY | 20 | Sep 3, 2026 | clinicaltrials |
| NCT04749108 | Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma(GRECCAR14) | recruiting | Phase 2 / Phase 3 | 1,075 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05174169 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease(CIRCULATE-US) | recruiting | Phase 2 / Phase 3 | 1,912 | NRG OncologyOTHER | 3 | Sep 2, 2026 | clinicaltrials |
| NCT07381660 | SBRT Versus Surgical Resection for Small HCC | recruiting | Phase 3 | 390 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06923475 | Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma(NEODISCO) | recruiting | Phase 2 / Phase 3 | 150 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06958328 | Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer(LAP100) | recruiting | Phase 3 | 356 | NRG OncologyOTHER | 2 | Aug 25, 2026 | clinicaltrials |
| NCT07669519 | Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy(NuvastaticTM) | recruiting | Phase 3 | 180 | Natureceuticals Sdn BhdINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT03257033 | Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC(TIGeR-PaC) | recruiting | Phase 3 | 190 | RenovoRxINDUSTRY | 2 | Aug 24, 2026 | clinicaltrials |
| NCT06467357 | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer(DESTINY-BTC01) | recruiting | Phase 3 | 620 | AstraZenecaINDUSTRY | 27 | Aug 19, 2026 | clinicaltrials |
| NCT07001748 | Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity(STOPGAP II) | recruiting | Phase 2 / Phase 3 | 148 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06119867 | CompariSon Between the EuroPeAn and Japanese pathologiCal InvEstigation for Colon Cancer (SPACE)(SPACE) | recruiting | Phase 3 | 430 | Russian Society of Colorectal SurgeonsOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07166406 | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | recruiting | Phase 3 | 226 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07262567 | Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer | recruiting | Phase 3 | 320 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05534087 | Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)(CLAUDIA) | recruiting | Phase 3 | 236 | Seoul National University HospitalOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06731478 | Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 3 | 726 | Daiichi SankyoINDUSTRY | 26 | Aug 10, 2026 | clinicaltrials |
| NCT07722494 | IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer | recruiting | Phase 3 | 550 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07475026 | A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence(Neo-LENTIS) | recruiting | Phase 3 | 198 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06644781 | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | recruiting | Phase 3 | 510 | Daiichi SankyoINDUSTRY | 17 | Aug 4, 2026 | clinicaltrials |
| NCT07629817 | Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy(HCHTOG2603) | recruiting | Phase 3 | 1,044 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06622057 | D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer | recruiting | Phase 3 | 240 | InnoPharmax Inc.INDUSTRY | 2 | Jul 30, 2026 | clinicaltrials |
| NCT07736495 | Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis | recruiting | Phase 2 / Phase 3 | 50 | Ain Shams UniversityOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06593431 | Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial | recruiting | Phase 3 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07582315 | A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) | recruiting | Phase 3 | 538 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07606599 | A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure | recruiting | Phase 3 | 398 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05253651 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer(MOUNTAINEER-03) | recruiting | Phase 3 | 400 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 25 | Jul 22, 2026 | clinicaltrials |
| NCT06796803 | Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) | recruiting | Phase 2 / Phase 3 | 398 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07710885 | Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer(FOENIX-BTC) | recruiting | Phase 3 | 784 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 4 | Jul 17, 2026 | clinicaltrials |
| NCT07487896 | A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy | recruiting | Phase 3 | 440 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07554456 | A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) | recruiting | Phase 2 / Phase 3 | 90 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06205485 | Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer(NEO-RT) | recruiting | Phase 3 | 250 | Canadian Cancer Trials GroupNETWORK | 2 | Jul 14, 2026 | clinicaltrials |
| NCT07436741 | Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer | recruiting | Phase 3 | 106 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07692152 | Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma | recruiting | Phase 3 | 350 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07518147 | A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment | recruiting | Phase 3 | 438 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07304271 | Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis(IPa-Gastric) | recruiting | Phase 3 | 262 | Magnus NilssonOTHER | 3 | Jul 7, 2026 | clinicaltrials |
| NCT07549399 | SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC(CRITⅡ) | recruiting | Phase 3 | 204 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03051464 | Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery(MORPHEUS) | recruiting | Phase 2 / Phase 3 | 131 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 2 | Jun 30, 2026 | clinicaltrials |
| NCT06794086 | SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases(SPARKLE-L) | recruiting | Phase 3 | 24 | Jun HuangOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06346197 | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas(CIME) | recruiting | Phase 3 | 132 | Centre Leon BerardOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07669454 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.(NuvastaticTM) | recruiting | Phase 3 | 250 | Natureceuticals Sdn BhdINDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
| NCT06642844 | Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment(PHARBEVACOL) | recruiting | Phase 3 | 244 | University Hospital, ToursOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05593458 | Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1(TACTIC) | recruiting | Phase 3 | 190 | Zhejiang UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07188025 | ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer(REACT) | recruiting | Phase 3 | 103 | Erasmus Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06783491 | Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer(FOXHIPECT4) | recruiting | Phase 3 | 1,083 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 8, 2026source: clinicaltrials